Companies · Biotech / Pharma
GOLETA · Biotech / Pharma · refined from filed group “Other”
Diligence memoA one-page analyst read on Laxmi Therapeutic Devices, Inc. — recommendation, valuation, rhythm, risks.→Laxmi Therapeutic Devices, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Laxmi Therapeutic Devices, Inc. is one of 227 Biotech / Pharma companies tracked from GOLETA. By capital raised it ranks among the largest (ahead of 90% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.
Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.
Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 90% of sector peers (real $). Modeled value above 65% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 21.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Laxmi Therapeutic Devices, Inc. this company | Series A | $58.2M | $75.2M | 1.93× |
| Accipiter Biosciences Inc. | Series A | $14.2M | $75.0M | 1.93× |
| Nanospectra Biosciences Inc | Series A | $22.3M | $58.9M | 1.52× |
| Ten Bay Bio, Inc. | Series A | $11.5M | $58.5M | 1.50× |
| Genomic Life, Inc. | Series A | $10.0M | $55.9M | 1.44× |
| NJ BIO, Inc. | Series A | $5.6M | $55.0M | 1.42× |
| Araceli Biosciences Inc. | Series A | $14.5M | $50.4M | 1.30× |
| Nalu Bio, Inc. | Series A | $4.8M | $48.4M | 1.25× |
| 3F Bio Ltd | Series A | $7.2M | $45.3M | 1.17× |
| PharmaCCX, Inc. | Series A | $11.7M | $45.1M | 1.16× |
| Aion Therapeutic Inc. | Series A | $5.8M | $38.9M | 1.00× |
| Topos Bio, Inc. | Series A | $9.0M | $37.5M | 0.96× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $1.5M | 2016-07-15 | $7.5M | $61.7M | 85% |
| Seed | $2.5M | 2017-10-30 | $12.5M | $102.9M | 90% |
| Seed | $2.5M | 2017-10-30 | $12.5M | $102.9M | 90% |
| Series A | $6.0M | 2019-12-02 | $27.3M | $201.0M | 90% |
| Series A | $6.0M | 2020-06-01 | $27.3M | $201.0M | 90% |
| Seed | $3.6M | 2020-06-01 | $18.0M | $148.1M | 90% |
| Series A | $13.2M | 2021-03-03 | $60.0M | $323.8M | 90% |
| Series A | $9.0M | 2022-07-26 | $40.9M | $115.2M | 90% |
| Series A | $5.0M | 2023-11-29 | $22.7M | $34.2M | 90% |
| Series A | $5.3M | 2024-07-31 | $24.2M | $26.7M | 90% |
| Series A | $11.0M | 2024-07-31 | $50.0M | $55.1M | 90% |
| Series A | $13.0M | 2024-07-31 | $59.1M | $65.1M | 90% |
| Series A | $15.0M | 2024-07-31 | $68.2M | $75.2M | 90% |
| Series A | $5.0M | 2024-07-31 | $22.7M | $25.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Peter Rule | — | 2 other | 2024-07 |
| Matthew Berger | — | 1 other | 2021-03 |
| Bill Van Antwerp | — | — | 2016-07 |
| Bill Van Antwery | — | — | 2019-12 |
| Greg Snelson | — | — | 2022-07 |
| John Gerngross | — | — | 2016-07 |
| Luke Theogarajan | — | — | 2016-07 |
| Rachael Scherer | — | — | 2021-03 |
| Radhika Krishman | — | — | 2019-12 |
| Radhika Krishnan | — | — | 2020-06 |
| Richard Low | — | — | 2016-07 |
| Sumita Pennathur | — | — | 2016-07 |
Laxmi Therapeutic Devices, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Swift Biosciences, Inc. | Biotech / Pharma | Series A | $31.5M | $134.0M | same sector · same stage |
| Ascus Biosciences, Inc. | Biotech / Pharma | Series A | $28.7M | $167.5M | same sector · same stage |
| Advanced Bio Development, Inc. | Biotech / Pharma | Series A | $28.2M | $435.7M | same sector · same stage |
| Ensysce Biosciences, Inc. | Biotech / Pharma | Series A | $25.4M | $7.9M | same sector · same stage |
| Intelligent Bio Solutions Inc. | Biotech / Pharma | Series A | $23.9M | $25.8M | same sector · same stage |
| Nanospectra Biosciences Inc | Biotech / Pharma | Series A | $22.3M | $58.9M | same sector · same stage |
| Arcadia Biosciences, Inc. | Biotech / Pharma | Series B | $58.4M | $7.8M | same sector |
| Wheeler Bio, Inc. | Biotech / Pharma | Series B | $59.9M | $123.8M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Ajaya Bio, Inc. | Biotech / Pharma | Pre-Seed | $778K | 80% |
| Mirata BioPharma, LLC | Pharma | Pre-Seed | $23.7M | 80% |
| Fairfield Bio, Inc. | Biotech / Pharma | Pre-Seed | $797K | 80% |
| Yatiri Bio, Inc. | Biotech / Pharma | Seed | $18.1M | 79% |
| Arcadia Biosciences, Inc. | Biotech / Pharma | Series B | $7.8M | 79% |
| Laxco, Inc. | Other | Pre-Seed | $23.1M | 78% |
| Luyef Biotechnologies Inc | Biotech / Pharma | Pre-Seed | $4.6M | 78% |
| Slingshot Biosciences, Inc. | Biotech / Pharma | Series B | $335.1M | 78% |
See where Laxmi Therapeutic Devices, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Laxmi Therapeutic Devices, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.